Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults
about
Obesity Is Not Associated with Antimicrobial Treatment Failure for Intra-Abdominal Infection.Dosing of antibacterial agents in obese adults: does one size fit all?The Daniel K. Inouye College of Pharmacy Scripts: Obesity: The Drug Dose Debate.Pharmacokinetics of Antimicrobials in Obese Children.Preventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens.Quantification and validation of HPLC-UV and LC-MS assays for therapeutic drug monitoring of ertapenem in human plasma.Assays for determination of ertapenem for applications in therapeutic drug monitoring, pharmacokinetics and sample stability.Outbreak of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae sequence type 11 in Taiwan in 2011.Case-control study of drug monitoring of β-lactams in obese critically ill patients.Doripenem Treatment during Continuous Renal Replacement TherapyErtapenem: the new carbapenem 5 years after first FDA licensing for clinical practice.Antimicrobial dosing considerations in obese adult patients.Pharmacokinetic and Pharmacodynamic Evaluation of a Weight-Based Dosing Regimen of Cefoxitin for Perioperative Surgical Prophylaxis in Obese and Morbidly Obese PatientsPopulation Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery.Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind.Polypharmacy and food-drug interactions among older persons: a review.Antibiotic dosing in obesity: the search for optimum dosing strategies.Pharmacokinetics of ertapenem in colorectal tissue.Carbapenem susceptibility breakpoints, clinical implications with the moving target.Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.Quantification and validation of ertapenem using a liquid chromatography-tandem mass spectrometry method.Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.Population pharmacokinetics of ertapenem in juvenile and old rats.The effect of obesity on clinical outcomes in presumed sepsis: a retrospective cohort study.Serum in vivo and in vitro activity of single dose of ertapenem in surgical obese patients for prevention of SSIs.Cefepime dosing in the morbidly obese patient population.Drug and nutrition interactions: not just food for thought.Dosing of Ertapenem in an Extreme Obesity: A Case Report of 250 kg Patient.No role for patient body weight on renal function assessment for drug dosing.The Pharmacokinetics of 2000 mg Ertapenem in Tuberculosis Patients.Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit.
P2860
Q30277073-29EBC79D-459E-4DC5-B5C6-522B7AEC222CQ30362353-50211C1F-6198-4E97-A653-970445F3B3ECQ33763123-2AD0B23D-9EF6-4F3F-A931-D185E2C46FAFQ33855312-540F8FB9-6F82-4E75-B9E3-F3778162BEEFQ33995500-1F978026-7C92-4C8B-8090-0E6D1983853CQ34445380-1A7ED78D-C52F-44E2-80B6-F6CADBD96F4AQ35218071-303B2CCC-FB87-4261-93AE-7481AB43A52AQ36276831-8B67C1D2-DC14-41E6-85BB-588B5B12C72BQ36558332-39B8BBAF-5482-4486-9539-AF2C0E4877C4Q36644597-52AFB231-21C9-41BE-96E8-79ABB7B26D3DQ36719706-837DD6E0-2230-448C-A030-93DA12860617Q36892796-323E4277-263E-4941-B8DB-F684C19CA49FQ37287895-674190A7-44F2-42FE-ADD1-DFCE32F89483Q37538609-141CB03A-4DF3-42B9-94EB-1B838F823409Q37771799-B448D292-04B0-4F0B-9B5A-EA38BCD1AD6EQ38060181-B09AB5CA-36C9-40C7-BC15-B024495475DCQ38397264-C1DFF515-FE2B-49EF-A8CA-8D272C7BCA20Q38479091-4D218E22-50EC-4253-A732-FBEC4532029CQ38751264-35977C8C-DDB2-42D4-AB6D-A5240F2AA128Q38991205-85F90A1F-2DEF-4A83-8E8D-BBDE6AD8322BQ41075817-520243F2-9680-432A-8849-8DE7E554839CQ41876999-6082791F-2DEC-45E2-BDFF-728C6675E0ACQ42264085-6F3CA3EC-578A-47BD-9A28-C54646D8AAE3Q43827300-3717176B-A9BA-482C-BD82-3E8654928F20Q44165112-F644E86C-7A30-4E94-94F5-5418FC3D8F94Q44189639-65937911-33B6-4E73-BB7C-F8437195C4EDQ45349818-EB50EA07-26F6-489B-853A-7E130F303229Q47111465-527D44FC-B18C-4B7F-9E0D-35FE2E067832Q47223964-BA6F8E38-A08F-4E68-B263-B6BABCF7B6CAQ50028072-87C776DF-F44E-4983-B1B0-CDA6B95B2E2BQ54561986-150D7E62-F79D-48E2-A7FA-4F6F35183722Q54766719-6799A015-CFAC-4325-ADA5-C4A517ECFA96
P2860
Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Comparative pharmacokinetics a ...... se, and extremely obese adults
@ast
Comparative pharmacokinetics a ...... se, and extremely obese adults
@en
Comparative pharmacokinetics a ...... se, and extremely obese adults
@nl
type
label
Comparative pharmacokinetics a ...... se, and extremely obese adults
@ast
Comparative pharmacokinetics a ...... se, and extremely obese adults
@en
Comparative pharmacokinetics a ...... se, and extremely obese adults
@nl
prefLabel
Comparative pharmacokinetics a ...... se, and extremely obese adults
@ast
Comparative pharmacokinetics a ...... se, and extremely obese adults
@en
Comparative pharmacokinetics a ...... se, and extremely obese adults
@nl
P2093
P2860
P1476
Comparative pharmacokinetics a ...... se, and extremely obese adults
@en
P2093
P2860
P304
P356
10.1128/AAC.50.4.1222-1227.2006
P407
P577
2006-04-01T00:00:00Z